CWH41 Antibody

What is CWH41 and why is it significant in research?

CWH41 is a gene in Saccharomyces cerevisiae that encodes glucosidase I (Cwh41p), an enzyme responsible for initiating the trimming of terminal α-1,2-glucose residues in the N-glycan processing pathway within the endoplasmic reticulum (ER) . The enzyme specifically removes the outermost α-1,2-glucose residue from Glc3Man9GlcNAc2 oligosaccharide chains attached to newly synthesized proteins . CWH41 encodes a novel type II integral membrane N-glycoprotein located in the endoplasmic reticulum .

The significance of CWH41 in research stems from several important aspects. First, it serves as an excellent model system for studying N-glycan processing and quality control mechanisms in the ER. Second, mutations in CWH41 demonstrate how defects in glycosylation pathways can indirectly affect seemingly unrelated cellular processes such as cell wall integrity . Third, its involvement in cell wall assembly makes it relevant to antifungal research and drug development strategies. Finally, the protein connects fundamental glycobiology to structural integrity of fungal cells, making it important for both basic and applied research contexts.

Research on CWH41 has broad implications for understanding protein folding quality control, cellular stress responses, and fungal pathogenesis. The antibodies targeting this protein enable researchers to track its expression, localization, and interactions with other proteins in these important biological processes.

How does CWH41 function in glycoprotein processing?

CWH41 functions at the initial step of N-glycan processing in the endoplasmic reticulum as glucosidase I. After the transfer of the core oligosaccharide (Glc3Man9GlcNAc2) to nascent proteins in the ER, Cwh41p specifically removes the outermost α-1,2-linked glucose residue from the triglucosyl cap of N-linked glycans . This trimming initiates a sequential process where glucosidase II subsequently removes the two remaining α-1,3-linked glucose residues to continue the glycan processing pathway .

This glucose trimming process is crucial for proper glycoprotein folding and quality control in the ER. The sequential removal of glucose residues creates specific glycan structures that are recognized by ER-resident chaperones like calnexin and calreticulin, which assist in protein folding. When glucose trimming is impaired, as in cwh41Δ mutants, glycoproteins retain their glucose residues, potentially interfering with proper folding.

Experimental evidence from studies using glucosidase inhibitors such as 1-deoxynojirimycin or castanospermine has shown that blocking glucose removal causes accumulation and sometimes degradation of glycoproteins in the ER . These observations demonstrate that CWH41-mediated glucose trimming is essential for glycoprotein processing and subsequent trafficking through the secretory pathway. The consequence of impaired processing appears to be accumulation of misfolded proteins in the ER, activation of ER stress responses, and possible degradation of certain glycoproteins .

What is the relationship between CWH41 and cell wall assembly in yeast?

Compelling evidence for this indirect relationship comes from genetic studies involving the ALG5 gene, which encodes dolichol-P-glucose synthase. In an alg5Δ mutant, which cannot add glucose residues to N-glycans, wild-type levels of β-1,6-glucan are maintained despite the lack of glucose on the glycans. Most significantly, the double mutant alg5Δcwh41Δ exhibits the same phenotype as the alg5Δ single mutant with normal levels of cell wall β-1,6-glucan . This indicates that the reduced β-1,6-glucan in cwh41Δ mutants stems from the abnormal presence of unprocessed glucose residues on N-glycans, not the absence of Cwh41p activity itself.

The mechanism linking unprocessed N-glycans to reduced β-1,6-glucan synthesis involves the stability and function of proteins required for β-1,6-glucan assembly. Specifically, Kre6p, a putative Golgi glucan synthase involved in β-1,6-glucan synthesis, is selectively unstable in cwh41Δ strains . This suggests that proper N-glycan processing is necessary for the stability and function of enzymes directly involved in cell wall construction, establishing an indirect but critical connection between CWH41 and cell wall integrity.

What phenotypes are associated with CWH41 mutations?

CWH41 mutations result in several distinct phenotypes that highlight its importance in cellular processes and provide valuable experimental readouts for researchers working with CWH41 antibodies:

These phenotypes collectively demonstrate how disruption of N-glycan processing can have wide-ranging effects on cell wall integrity, protein stability, and cell growth, making CWH41 an important component in fungal cell biology.

How can CWH41 antibodies be used in localization studies?

CWH41 antibodies are valuable tools for localization studies aimed at understanding the distribution and trafficking of Cwh41p within cellular compartments. Here's a methodological approach for conducting such studies:

Immunofluorescence Microscopy Protocol:

• Cell Preparation:

  • Grow yeast cells to mid-log phase in appropriate media

  • Fix cells with 3.7% formaldehyde for 1 hour at room temperature

  • Wash cells with phosphate buffer containing sorbitol (PBS + 1.2M sorbitol)

  • Digest cell walls partially with zymolyase (1mg/ml) for 20-30 minutes

• Antibody Labeling:

  • Permeabilize cells with 0.1% Triton X-100

  • Block with 1% BSA in PBS for 30 minutes

  • Incubate with primary anti-CWH41 antibody (1:100-1:500 dilution) overnight at 4°C

  • Wash extensively with PBS

  • Incubate with fluorophore-conjugated secondary antibody for 1-2 hours

  • Counterstain with DAPI (1μg/ml) to visualize nuclei

• Co-localization Studies:

  • Combine anti-CWH41 antibodies with markers for specific cellular compartments:

    • Anti-Kar2 for ER localization

    • Anti-Sec61 for ER membrane

    • Anti-Anp1 for cis-Golgi

    • Anti-Sec7 for trans-Golgi

• Confocal Microscopy Analysis:

  • Examine cells using appropriate filter sets

  • Collect Z-stack images to visualize the three-dimensional distribution

  • Analyze co-localization using image analysis software (Pearson's correlation coefficient)

Researchers should be aware that standard immunofluorescence techniques may require optimization for yeast cells due to their small size and thick cell wall. Alternative approaches include immunoelectron microscopy for higher resolution or the use of fluorescent protein fusions (GFP-CWH41) for live-cell imaging. Based on its function, Cwh41p would be expected to show primarily ER localization, consistent with its role as an ER-resident enzyme involved in early N-glycan processing.

What are the methodological considerations for using CWH41 antibodies in immunoprecipitation experiments?

When using CWH41 antibodies for immunoprecipitation (IP) experiments, researchers should consider several critical methodological factors to ensure successful and interpretable results:

Antibody Selection and Validation:

• Choose antibodies raised against conserved epitopes of Cwh41p

• Verify antibody specificity using Western blot analysis with wild-type and cwh41Δ mutant lysates

• Test both polyclonal and monoclonal antibodies, as they may differ in IP efficiency

• Consider using antibodies against epitope-tagged versions of Cwh41p (HA, Myc, FLAG) if native antibodies show poor performance

Cell Lysis Optimization:

• Since Cwh41p is a membrane-bound ER protein, standard lysis buffers may be insufficient

• Use detergent-based lysis buffers containing 1% digitonin, 1% Triton X-100, or 0.5% NP-40

• Include protease inhibitors (PMSF, protease inhibitor cocktail) to prevent degradation

• Consider crosslinking (1-2% formaldehyde) before lysis to stabilize protein-protein interactions

• Perform lysis at 4°C to minimize proteolytic degradation

Immunoprecipitation Protocol:

• Pre-clear cell lysates with protein A/G beads to reduce non-specific binding

• Incubate cleared lysates with anti-CWH41 antibody (5-10 μg) overnight at 4°C

• Add protein A/G beads and incubate for 2-4 hours at 4°C

• Wash extensively (4-6 times) with decreasing detergent concentrations

• Elute bound proteins with either low pH buffer, high salt, or by boiling in SDS sample buffer

Controls and Validation:

• Include negative controls: IgG isotype control and lysate from cwh41Δ strains

• Use positive controls: IP with antibodies against known interaction partners

• Validate results with reverse IP using antibodies against identified interaction partners

• Consider SILAC or other quantitative proteomics approaches to distinguish specific from non-specific interactors

IP experiments with CWH41 antibodies can be particularly challenging due to the membrane-associated nature of Cwh41p and its location in the ER. Researchers should be prepared to test multiple lysis conditions and antibody concentrations to achieve optimal results for identifying Cwh41p-interacting proteins that might be involved in ER quality control or cell wall biogenesis pathways.

How can researchers distinguish between direct and indirect effects of CWH41 in β-1,6-glucan biosynthesis?

Distinguishing between direct and indirect effects of CWH41 in β-1,6-glucan biosynthesis requires a strategic experimental approach that combines genetic, biochemical, and cell biological techniques. The search results indicate that CWH41's role in β-1,6-glucan synthesis is indirect , but here's a comprehensive methodological framework for addressing this question:

Genetic Bypass Experiments:
The most definitive approach involves creating genetic backgrounds that bypass the need for CWH41 function in N-glycan processing while maintaining all other cellular functions. This was demonstrated in the research where alg5Δcwh41Δ double mutants were created . The reasoning is:

• If CWH41 directly participates in β-1,6-glucan synthesis, then preventing N-glycan glucose addition (alg5Δ) should not rescue the β-1,6-glucan defect in cwh41Δ mutants

• If CWH41's role is indirect (through N-glycan processing), then preventing glucose addition should eliminate the need for glucose removal (CWH41 function)

The observation that alg5Δcwh41Δ double mutants have wild-type levels of β-1,6-glucan strongly supports the indirect role model .

Biochemical Assays:

• In vitro β-1,6-glucan synthesis assays with purified components:

  • Establish a cell-free system for β-1,6-glucan synthesis

  • Test whether purified Cwh41p directly affects β-1,6-glucan polymerization

  • Compare activity with and without Cwh41p protein

• Analysis of substrate utilization:

  • Determine if Cwh41p can utilize UDP-glucose or other β-1,6-glucan precursors

  • Use radiolabeled substrates to track incorporation into glucan chains

Protein Stability and Localization Studies:

• Examine the stability and localization of known β-1,6-glucan synthetic machinery:

  • Measure protein levels of Kre6p and other β-1,6-glucan synthesis components in wild-type and cwh41Δ strains

  • Use cycloheximide chase experiments to assess protein stability

  • Examine protein glycosylation status using endoglycosidase treatments

• Create glycosylation site mutants of key β-1,6-glucan synthetic enzymes:

  • Identify N-glycosylation sites in Kre6p and related proteins

  • Mutate these sites to prevent glycosylation

  • Test if these mutants are still affected by cwh41Δ mutations

These approaches collectively allow researchers to differentiate between direct enzymatic involvement and indirect effects mediated through protein quality control mechanisms in the ER.

What genetic interaction studies have revealed insights about CWH41 function?

Genetic interaction studies have provided crucial insights into CWH41 function, particularly regarding its role in cell wall integrity and β-1,6-glucan synthesis. These studies reveal functional relationships between genes and uncover biological pathways that might not be apparent from single gene analyses. Here are the key findings from genetic interaction studies involving CWH41:

Strong Synthetic Interactions with KRE Genes:

• CWH41 and KRE6 Interaction:

  • The cwh41Δkre6Δ double mutant is non-viable (synthetic lethality) in genetic backgrounds where single mutants are viable

  • This synthetic lethality disappears in an alg5Δ background, as the triple mutant alg5Δcwh41Δkre6Δ is viable

  • This interaction suggests that Cwh41p and Kre6p function in parallel pathways that both contribute to an essential cellular process, likely cell wall integrity

• CWH41 and KRE1 Interaction:

  • The cwh41Δkre1Δ double mutant displays severe synergistic defects :

    • Severely slow growth phenotype

    • 75% reduction in β-1,6-glucan levels (compared to 50% in cwh41Δ single mutants)

    • Secretion of cell wall glucomannoprotein Cwp1p

  • Similar to the KRE6 interaction, the genetic interaction with KRE1 is abolished in an alg5Δ background

Protein Stability Effects:

Genetic studies combined with protein analysis revealed that Kre6p, a putative Golgi glucan synthase, is selectively unstable in cwh41Δ strains . This finding provides a mechanistic explanation for the genetic interactions:

• The absence of Cwh41p function leads to improper N-glycosylation

• This improper glycosylation affects the stability or function of Kre6p

• Reduced Kre6p function then impairs β-1,6-glucan synthesis

Suppressor Analysis:

Overexpression of KRE6 renders cwh41Δ strains resistant to Calcofluor White (CFW) , suggesting that:

• The CFW sensitivity of cwh41Δ is partly due to reduced Kre6p function

• Increasing Kre6p levels can compensate for the indirect effects of cwh41Δ on cell wall integrity

These genetic interaction studies collectively support a model where Cwh41p's primary function is in N-glycan processing, but through this role, it indirectly affects cell wall biosynthesis by influencing the stability and function of proteins directly involved in β-1,6-glucan assembly.

How does antibody profiling for CWH41 differ between candidiasis patients and healthy individuals?

While the search results do not specifically address antibody profiling for CWH41 in candidiasis patients versus healthy individuals, they do provide information about serological profiling of Candida albicans proteins that can inform our understanding of how such studies might be conducted and interpreted for CWH41 . Here's a methodological framework for analyzing CWH41 antibody responses:

Serological Profiling Approaches for CWH41 Antibodies:

Based on the C. albicans microarray study described in the search results , a similar methodology could be applied to specifically analyze CWH41 antibody responses:

• Protein Microarray Technology:

  • Include recombinant CWH41 protein on fungal protein microarrays

  • Probe arrays with sera from different patient groups:

    • Acute candidemia patients

    • Convalescent candidemia patients (early and mid-stage)

    • Uninfected hospital patients

    • Healthy individuals

  • Quantify IgG responses to CWH41 across these groups

• Patient Stratification:

  • Compare CWH41 antibody levels across disease states

  • Track antibody levels longitudinally through infection and recovery

  • Correlate antibody levels with disease severity and outcomes

Expected Patterns Based on Related Research:

The search results indicate that for many Candida cell surface antigens, there is a permanent host-pathogen interplay in immunocompetent individuals, resulting in detectable antibody levels even in healthy people . For CWH41 specifically, we might expect:

• Baseline Antibody Levels:

  • Healthy individuals likely maintain detectable anti-CWH41 antibodies due to commensal colonization

  • These baseline levels represent the "immunological footprint" of normal fungal exposure

• Acute Infection Response:

  • During acute candidiasis, antibody levels might not immediately differ from baseline

  • This is consistent with the observation that many top serodominant antigens show similar levels between acute candidemia patients and controls

• Convalescent Phase Dynamics:

  • Significant differences might emerge during convalescence as the adaptive immune response develops

  • Based on patterns seen with other antigens, CWH41 antibody levels might increase during weeks 4-12 post-infection

This approach allows researchers to understand how the immune response to CWH41 evolves during infection and might identify patterns useful for diagnostic or prognostic applications.

What are the best experimental approaches to study CWH41 post-translational modifications?

Studying post-translational modifications (PTMs) of CWH41 requires a comprehensive analytical approach combining biochemical, proteomic, and genetic techniques. Here are the best experimental approaches for characterizing CWH41 PTMs:

Mass Spectrometry-Based Proteomic Analysis:

• Sample Preparation:

  • Express and purify CWH41 with epitope tags (His, FLAG, HA) for immunoprecipitation

  • Extract from native sources using optimized membrane protein protocols

  • Use both reducing and non-reducing conditions to preserve disulfide bonds when relevant

• PTM Enrichment Strategies:

  • For glycosylation: Use lectin affinity chromatography (ConA for mannose-rich glycans)

  • For phosphorylation: Employ TiO₂ or IMAC (immobilized metal affinity chromatography)

  • For ubiquitination: Use anti-ubiquitin antibodies or TUBE (tandem ubiquitin binding entities)

• MS Analysis Pipeline:

  • Perform bottom-up proteomics with different proteases (trypsin, chymotrypsin) to maximize coverage

  • Use electron transfer dissociation (ETD) for intact glycopeptide analysis

  • Implement parallel reaction monitoring (PRM) for targeted quantification of modified peptides

Site-Directed Mutagenesis:

• Identification of Potential Modification Sites:

  • Predict N-glycosylation sites using bioinformatics tools (NetNGlyc, GlycoEP)

  • Identify conserved motifs for other PTMs (phosphorylation, ubiquitination)

• Mutational Analysis:

  • Generate site-directed mutants of predicted modification sites

  • Create alanine substitutions for Ser/Thr phosphorylation sites

  • Replace Asn with Gln in N-glycosylation motifs (N-X-S/T)

  • Assess functional consequences through complementation assays in cwh41Δ strains

Glycobiology-Specific Approaches:

Since CWH41 is known to be an N-glycoprotein located in the ER membrane , special attention should be given to characterizing its glycosylation:

• Glycosidase Digestions:

  • Treat purified CWH41 with endoglycosidase H (sensitive to high-mannose ER-type glycans)

  • Compare with PNGase F treatment (removes all N-linked glycans)

  • Analyze mobility shifts by SDS-PAGE

• Metabolic Labeling:

  • Use radioactive mannose labeling to monitor glycan addition and processing

  • Apply pulse-chase experiments to track glycoprotein maturation

By combining these complementary approaches, researchers can obtain a comprehensive picture of CWH41 post-translational modifications and understand how they influence protein function, stability, localization, and interactions with other cellular components.